Travere Therapeutics, Inc.
TVTX • NASDAQ
Travere Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Eric Dube, with a market cap of $2.5B.
CEOEric Dube
Next Earnings
Upcoming earnings announcement for Travere Therapeutics, Inc.
Date
Thursday, April 30, 2026 (in 4 weeks)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.10
Revenue Estimate
$134.9M
Earnings History
Past 12 earnings reports for Travere Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 19, 2026 | Q4 2025 | $0.37Est: $0.24 | +54.2% | $129.7MEst: $145.6M | -10.9% |  10-K |
| Oct 30, 2025 | Q3 2025 | $0.59Est: -$0.17 | +447.1% | $164.9MEst: $105.0M | +57.0% | 10-Q |
| Aug 6, 2025 | Q2 2025 | $0.13Est: -$0.12 | +208.3% | $114.4MEst: $99.1M | +15.5% | 10-Q |
| May 1, 2025 | Q1 2025 | -$0.19Est: -$0.39 | +51.3% | $81.7MEst: $76.9M | +6.3% | 10-Q |
| Feb 20, 2025 | Q4 2024 | -$0.47Est: -$0.38 | -23.7% | $74.8MEst: $72.4M | +3.3% | 10-K |
| Oct 31, 2024 | Q3 2024 | -$0.46Est: -$0.68 | +32.4% | $62.9MEst: $60.5M | +4.0% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$0.65Est: -$0.86 | +24.4% | $52.2MEst: $50.2M | +4.0% | 10-Q |
| May 6, 2024 | Q1 2024 | -$1.51Est: -$0.99 | -52.5% | $41.4MEst: $42.9M | -3.4% | 10-Q |
| Feb 15, 2024 | Q4 2023 | -$0.94Est: -$1.26 | +25.4% | $45.1MEst: $41.5M | +8.5% | 10-K |
| Nov 7, 2023 | Q3 2023 | $2.27 | — | $37.1M | — | — |
| Aug 3, 2023 | Q2 2023 | -$0.77Est: -$1.16 | +33.6% | $59.7MEst: $53.9M | +10.7% | 10-Q |
| May 4, 2023 | Q1 2023 | -$0.82Est: -$1.17 | +29.9% | $57.0MEst: $50.6M | +12.6% | — |